Capricor Therapeutics (NASDAQ:CAPR) faces a three-month extension to the FDA review timeline for Deramiocel after the agency moved the PDUFA target action date for the Duchenne muscular dystrophy cell therapy from August 22 to November 22, 2026.
The extension follows Capricor’s submission of a major amendment containing 24-month open-label extension data from the Phase 3 HOPE-3 study and additional analyses supporting a refined proposed indication focused on upper limb function.
Key Investor Takeaways
- Capricor Therapeutics (NASDAQ:CAPR) now faces a November 22, 2026 PDUFA date for Deramiocel, extending the regulatory timeline by three months.
- The FDA classified Capricor’s new submission as a major amendment, requiring additional review time rather than completing its decision under the previous August deadline.
- The amendment adds 24-month HOPE-3 open-label extension data and further robustness analyses supporting a proposed indication centred on upper limb function.
- HOPE-3 met its primary endpoint, demonstrating a statistically significant benefit in upper limb function, according to Capricor.
- FDA approval remains uncertain, but CBER accepted the additional information for review while citing the significant unmet medical need in Duchenne muscular dystrophy.
Why CAPR Stock Is in Focus
The immediate development for Capricor investors is a delay to the regulatory decision on Deramiocel, the company’s lead cell therapy candidate.
Following discussions with the FDA after a July 2026 Advisory Committee meeting, Capricor amended its BLA with an additional year of open-label follow-up from HOPE-3 and further analyses of the clinical data.
The company is asking the FDA to consider the existing and newly submitted evidence in support of a refined proposed indication focused specifically on upper limb function, which was the primary endpoint of the pivotal Phase 3 trial.
CBER accepted the amendment but classified it as major, triggering the three-month extension. The new November 22 target gives regulators additional time to evaluate the expanded dataset and proposed indication.
Why This Matters for Investors
The PDUFA extension postpones a major binary regulatory catalyst for CAPR, extending the period of uncertainty around whether Deramiocel will reach the U.S. market.
Importantly, the delay is tied to Capricor’s submission of additional clinical information rather than a disclosed new safety issue. The company said the 24-month extension data and robustness analyses strengthen the evidence supporting an indication focused on preserving upper limb function.
That refined indication may become central to the regulatory outcome. HOPE-3 achieved statistical significance on its primary upper limb function endpoint, giving Capricor a clinical basis for narrowing the proposed use around an area where the pivotal trial demonstrated benefit.
However, acceptance of the amendment for review should not be interpreted as an indication of eventual approval. The FDA is continuing to evaluate both the existing BLA and the additional information, leaving the regulatory outcome unresolved until the review is completed.
The stakes are also significant for Capricor’s broader pipeline positioning. Deramiocel is its lead candidate, while the company is separately developing its StealthX exosome platform. A regulatory decision on Deramiocel could therefore materially influence the company’s near-term development and commercial narrative.
What to Watch Next
November 22, 2026 is now the principal regulatory catalyst for Capricor and Deramiocel.
Investors should watch for any additional FDA interactions or changes to the proposed indication as the agency reviews the 24-month HOPE-3 data and supporting analyses.
Approval could also have an additional regulatory asset attached: Deramiocel holds Rare Pediatric Disease designation, which Capricor says may qualify the company for a Priority Review Voucher upon approval.
Until the FDA completes its review, Deramiocel remains investigational and the outcome of the BLA remains uncertain.